A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Treatment With Single and Repeat Doses of Inhaled RV6153 in Healthy Subjects and Subjects With Stable Asthma.
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2016
At a glance
- Drugs RV 6153 (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors RespiVert
- 10 Jun 2017 Biomarkers information updated
- 03 Mar 2016 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 13 Jan 2016 Planned End Date changed from 1 Apr 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.